JVDI Advertisement
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarli, G
Right arrow Articles by Benazzi, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarli, G
Right arrow Articles by Benazzi, C
Journal of Veterinary Diagnostic Investigation, Vol 16, Issue 6, 542-547
Copyright © 2004 by American Association of Veterinary Laboratory Diagnosticians


Articles

E-cadherin immunoreactivity in canine mammary tumors

G Sarli, R Preziosi, L De Tolla, B Brunetti, and C Benazzi

Department of Veterinary Public Health and Animal Pathology, University of Bologna, Ozzano Emilia, 60066 Bologna, Italy.

The reduction or loss of E-cadherin (E-cad), a calcium-dependent epithelial cell adhesion molecule, has been associated with tumor dedifferentiation and invasiveness. The immunohistochemical pattern of E-cad expression was evaluated in formalin-fixed and paraffin-embedded sections of 6 normal mammary glands, 3 dysplasias, 12 benign tumors (8 benign mixed tumors, 4 adenomas), and 60 malignant tumors (12 stage 0, 29 stage I, 19 stage II) of the canine mammary gland. E-cadherin expression was classified as membranous, when on cell-cell boundaries, or as cytoplasmic, when in the form of a diffuse cytoplasmic staining. In addition, the percentage of E-cad-positive epithelial neoplastic cells was graded by a semiquantitative method, categorizing cases into a reduced (or -) type group, when showing less than 25% positivity, a reduced (or +/-) type group, when showing 25-75% positivity, and a preserved (or +) type group, when more than 75% positive cells were present. In the normal mammary gland, E-cad expression was evident in epithelial luminal cells. A stronger positivity was revealed in ductular than in alveolar luminal cells. The myoepithelial cells showed inconsistent, weak cytoplasmic positivity in the normal gland as well as in mammary tumors. In normal glands and benign and malignant noninvasive tumors, E-cad expression was mainly membranous and preserved in most of the epithelial cells. In stage I tumors, both membranous (38%) and cytoplasmic (62%) positivity were well represented, as well as preserved type (55%) and reduced type (45%) tumors. All stage II malignant tumors showed the highest frequency of cytoplasmic positivity (79%) and reduced type (62%) tumors.


This article has been cited by other articles:


Home page
Vet PatholHome page
B. Brunetti, G. Sarli, R. Preziosi, I. Monari, and C. Benazzi
E-Cadherin and {beta}-catenin Reduction Influence Invasion but not Proliferation and Survival in Canine Malignant Mammary Tumors
Vet. Pathol., November 1, 2005; 42(6): 781 - 787.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association of Veterinary Laboratory Diagnosticians, Inc.